NATICK,
Mass., May 19, 2022 /PRNewswire/ -- Avenge Bio,
Inc. ("Avenge" or the "Company"), a biotechnology company
developing the LOCOcyte™ immunotherapy platform for the precision
administration of potent immune effector molecules to treat solid
tumors, today announced that two abstracts were selected for
presentation as posters at the 25th Annual American
Society of Gene & Cell Therapy (ASGCT) Meeting on May 17 and 18, 2022.
"We are excited to present additional preclinical data that
support our lead development program, AVB-001, as we advance
towards filing an IND in Q2 2022 and a Phase 1 clinical trial in
ovarian cancer in 2H 2022," said Douglas
Carlson, Chief Operating and Financial Officer. "In
addition, we continue to build a robust data set for AVB-001, a
novel immunotherapy, in malignant pleural mesothelioma. All of our
development programs leverage Avenge's LOCOcyte™ platform to
deliver proprietary encapsulated engineered human cells to the
local tumor environment."
Details on Avenge's presentations at ASGTC are as
follows:
Poster Title: Tumor Adjacent IL-2 Cytokine Factories
for Eradication of Various Solid Tumor in Mice Through Cytotoxic
T-cell Activation with Safe and Predictable Dosing in Non-human
Primates.
Abstract #: 657
Date and Time: May 17, 2022, 5:30pm-6:30pm ET
Poster Title: Evaluation of Implantable Cytokine
Factories in Combination with Checkpoint Inhibitors for Eradication
of Malignant Pleural Mesothelioma (MPM) Tumors in Mice.
Abstract #: 1097
Date and Time: May 18, 2022, 5:30pm-6:30pm ET
The posters will be available on the Presentations and
Publications section of www.avengebio.com following the
conference.
About Avenge Bio
Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology
company developing transformative cell-based immunotherapeutic
products for the treatment of intractable solid tumors by
incorporating its LOCOcyte™ platform. The LOCOcyte™ platform
leverages proprietary engineered cells delivered to the local tumor
environment that generate high concentrations of immune effector
molecules in proximity to the tumor. This initiates a robust, local
and durable systemic immune response while avoiding toxicities
associated with systemic immunotherapies. Avenge's most advanced
product candidate, AVB-001, produces native IL-2 immunotherapy and
is initially being studied in metastatic peritoneal cancers such as
ovarian cancer. Avenge has additional pipeline candidates for the
treatment of a wide range of cancers including pancreatic, lung and
breast cancers. Avenge was founded in 2019 based upon technology
developed in the laboratory of Omid
Veiseh, Ph.D. and has an exclusive license from Rice University for this technology.
To learn more about Avenge visit: www.avengebio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avenge-bio-presents-preclinical-data-at-the-american-society-of-gene--cell-therapy-asgct-annual-meeting-301551364.html
SOURCE Avenge Bio, Inc.